Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity

Doxorubicin is the most effective single agent in the treatment of non‐Hodgkin's lymphoma (NHL). Its use is limited because of the cardiac toxicity primarily in elderly patients (pts) and in pts with history of cardiac disease. Liposomal doxorubicin has been proven to reduce cardiotoxicity. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigacci, Luigi, Annibali, Ombretta, Kovalchuk, Sofya, Bonifacio, Elisabetta, Pregnolato, Francesca, Angrilli, Francesco, Vitolo, Umberto, Pozzi, Samantha, Broggi, Serena, Luminari, Stefano, Merli, Francesco, Spina, Michele, Bolis, Silvia, Margiotta‐Casaluci, Gloria, Scalzulli, Rosario, Cox, Christina, Mamusa, Angela Maria, Santoro, Armando, Zinzani, Pier Luigi, Ferrari, Samantha, Gini, Guido, Vigliotti, Maria Luigia, Mulè, Antonino, Flenghi, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689940/
https://www.ncbi.nlm.nih.gov/pubmed/32542788
http://dx.doi.org/10.1002/hon.2764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689940/
https://www.ncbi.nlm.nih.gov/pubmed/32542788
http://dx.doi.org/10.1002/hon.2764

Ejemplares similares